Navigation Links
BioMarin to Present at the Deutsche Bank Healthcare Conference
Date:4/26/2011

NOVATO, Calif., April 26, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in Boston on Tuesday, May 3, 2011 at 3:30 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Barclays Global Healthcare Conference
2. BioMarin to Present at the Cowen Health Care Conference
3. BioMarin to Present at the Citi Global Healthcare Conference
4. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
5. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
6. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
7. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
8. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
9. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
10. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
11. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 The pen needles market is ... USD 1.65 billion in 2016, growing at a CAGR ... 2021. Over the years, the pen needles market ... to the growing demand for safety injections in the ... of safety pen needles with an aim to reduce ...
(Date:12/6/2016)... 6, 2016  BTL Aesthetics today announced the ... BTL Vanquish ME device was effectively redesigned for ... the targeted tissue. The result: Significantly better outcomes ... BTL Vanquish ME versus BTL Vanquish. ... and their patients with the most highly-advanced devices ...
(Date:12/6/2016)... , Dec. 6, 2016  Viking Therapeutics, Inc. ... biopharmaceutical company focused on the development of novel ... that the U.S. Food and Drug Administration (FDA) ... the treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is ... agonist that selectively regulates the expression of genes ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... Levels of a protein in the blood associated with ... online in the journal Radiology. , Heart disease and brain disease exact a major ... rapidly aging population. Damage to both organs often occurs at a subclinical stage, or ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance Agency, a ... the Sacramento/Folsom region, is initiating a charity event to raise support and awareness ... Chance treatment center in Sacramento works to provide area teens and families with ...
(Date:12/7/2016)... ... XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... Man’s ... Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition similar ... the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease is ...
(Date:12/7/2016)... ... December 07, 2016 , ... Texas Premier ... operations" carried out by unethical locksmith companies and is urging Search Engines to ... According to Texas Premier Locksmith, these fraudulent locksmith services take advantage of consumers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... WellnessPro Plus for consumers and healthcare professionals to manage chronic and acute ... the treatment modalities available in a single device. The announcement is part ...
Breaking Medicine News(10 mins):